Literature DB >> 10348236

Leptospirosis and Ebola virus infection in five gold-panning villages in northeastern Gabon.

E Bertherat1, A Renaut, R Nabias, G Dubreuil, M C Georges-Courbot.   

Abstract

An exhaustive epidemiologic and serologic survey was carried out in five gold-panning villages situated in northeastern Gabon to estimate the degree of exposure of to leptospirosis and Ebola virus. The seroprevalence was 15.7% for leptospirosis and 10.2% for Ebola virus. Sixty years after the last seroepidemiologic survey of leptospirosis in Gabon, this study demonstrates the persistence of this infection among the endemic population and the need to consider it as a potential cause of hemorrhagic fever in Gabon. There was no significant statistical correlation between the serologic status of populations exposed to both infectious agents, indicating the lack of common risk factors for these diseases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10348236     DOI: 10.4269/ajtmh.1999.60.610

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  21 in total

1.  The farmer who didn't need a wheel barrow.

Authors:  Willibald Hochholzer; Christina Orasch; Stefanie Huber; Christian Arranto; Sabina Hunziker
Journal:  BMJ Case Rep       Date:  2009-06-01

2.  Multiple circulating infections can mimic the early stages of viral hemorrhagic fevers and possible human exposure to filoviruses in Sierra Leone prior to the 2014 outbreak.

Authors:  Matthew L Boisen; John S Schieffelin; Augustine Goba; Darin Oottamasathien; Abigail B Jones; Jeffrey G Shaffer; Kathryn M Hastie; Jessica N Hartnett; Mambu Momoh; Mohammed Fullah; Michael Gabiki; Sidiki Safa; Michelle Zandonatti; Marnie Fusco; Zach Bornholdt; Dafna Abelson; Stephen K Gire; Kristian G Andersen; Ridhi Tariyal; Mathew Stremlau; Robert W Cross; Joan B Geisbert; Kelly R Pitts; Thomas W Geisbert; Peter Kulakoski; Russell B Wilson; Lee Henderson; Pardis C Sabeti; Donald S Grant; Robert F Garry; Erica O Saphire; Luis M Branco; Sheik Humarr Khan
Journal:  Viral Immunol       Date:  2015-02       Impact factor: 2.257

3.  Evaluating the frequency of asymptomatic Ebola virus infection.

Authors:  Placide Mbala; Marc Baguelin; Ipos Ngay; Alicia Rosello; Prime Mulembakani; Nikolaos Demiris; W John Edmunds; Jean-Jacques Muyembe
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2017-05-26       Impact factor: 6.237

4.  Comparing actual and perceived causes of fever among community members in a low malaria transmission setting in northern Tanzania.

Authors:  Julian T Hertz; O Michael Munishi; Joanne P Sharp; Elizabeth A Reddy; John A Crump
Journal:  Trop Med Int Health       Date:  2013-09-17       Impact factor: 2.622

5.  Potential mammalian filovirus reservoirs.

Authors:  A Townsend Peterson; Darin S Carroll; James N Mills; Karl M Johnson
Journal:  Emerg Infect Dis       Date:  2004-12       Impact factor: 6.883

6.  A review of epidemiological parameters from Ebola outbreaks to inform early public health decision-making.

Authors:  Maria D Van Kerkhove; Ana I Bento; Harriet L Mills; Neil M Ferguson; Christl A Donnelly
Journal:  Sci Data       Date:  2015-05-26       Impact factor: 6.444

7.  Serological patterns of brucellosis, leptospirosis and Q fever in Bos indicus cattle in Cameroon.

Authors:  Francesca Scolamacchia; Ian G Handel; Eric M Fèvre; Kenton L Morgan; Vincent N Tanya; Barend M de C Bronsvoort
Journal:  PLoS One       Date:  2010-01-21       Impact factor: 3.240

Review 8.  Clinical management of filovirus-infected patients.

Authors:  Danielle V Clark; Peter B Jahrling; James V Lawler
Journal:  Viruses       Date:  2012-09-21       Impact factor: 5.048

Review 9.  Ecologic and geographic distribution of filovirus disease.

Authors:  A Townsend Peterson; John T Bauer; James N Mills
Journal:  Emerg Infect Dis       Date:  2004-01       Impact factor: 6.883

Review 10.  Health risks of gold miners: a synoptic review.

Authors:  Ronald Eisler
Journal:  Environ Geochem Health       Date:  2003-09       Impact factor: 4.898

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.